Guard Therapeutics International AB (DPHA) AI Stock Analysis

Guard Therapeutics International AB

(Nasdaq OMX AB:DPHA)

Select Model

Rating:47Neutral

Price Target:SEK 1.00▼(-11.82% Downside)

Action:reiterated

Date:09/10/26

Weak financial performance from zero revenue, ongoing losses and eroding equity in this early-stage biotech is the dominant factor, only partially offset by a debt-free balance sheet. Neutral-to-mildly positive technical indicators provide limited support while negative P/E weighs on valuation.

Positive Factors

Clinical pipeline focusA focused lead asset addressing acute kidney injury and oxidative-stress-related renal disease gives the company a clearly defined development strategy. If clinical development succeeds, the therapeutic positioning could support meaningful product differentiation and create a foundation for future commercial growth.

Negative Factors

No commercial revenueZero reported revenue indicates that the business has not yet established commercial traction or an operating revenue base. This leaves near-term value creation dependent on successful clinical progress and future product approval, rather than on recurring sales that can independently fund development.

Guard Therapeutics International AB (DPHA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 50.56M
Dividend Yield: ―
Average Volume (3M): 33.02K
Price to Earnings (P/E): -0.4
Beta (1Y): 0.48
Revenue Growth: ―
EPS Growth: 70.76%
Country: Sweden
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Guard Therapeutics International AB Business Overview & Revenue Model

Company Description

Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard...

Guard Therapeutics International AB Financial Statement Overview

Summary

Pre-revenue biotech with consistent net losses and negative cash flows, though zero debt and slight TTM improvements offer limited positives.

Income Statement

15Very Negative

Balance Sheet

35Negative

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	-15.00K	-15.00K	-15.00K
EBITDA	-80.98M	-107.74M	-100.23M	-114.91M	-112.82M	-82.01M
Net Income	-80.99M	-108.85M	-96.07M	-113.32M	-110.76M	-82.16M
Balance Sheet
Total Assets	45.00M	54.14M	55.74M	85.23M	202.60M	190.44M
Cash, Cash Equivalents and Short-Term Investments	40.99M	49.83M	54.19M	83.74M	201.01M	188.60M
Total Debt	0	0	0	0	0	0
Total Liabilities	8.46M	13.51M	17.77M	18.49M	25.24M	14.66M
Stockholders Equity	36.54M	40.63M	37.97M	66.73M	177.36M	175.78M
Cash Flow
Free Cash Flow	-82.34M	-109.35M	-94.75M	-116.05M	-102.14M	-77.59M
Operating Cash Flow	-82.34M	-109.35M	-94.75M	-116.05M	-102.14M	-77.59M
Investing Cash Flow	0	0	0	0	-1,000	0
Financing Cash Flow	107.82M	107.22M	62.66M	-779.00K	112.60M	176.30M

Guard Therapeutics International AB Technical Analysis

Technical Analysis SentimentNegative

Last Price1.13

Price Trends

50DMA1.22Negative

100DMA1.36Negative

200DMA1.42Negative

Market Momentum

MACD-0.03Negative

RSI49.41Neutral

STOCH41.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DPHA, the sentiment is Negative. The current price of 1.13 is above the 20-day moving average (MA) of 1.10, below the 50-day MA of 1.22, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.41 is Neutral, neither overbought nor oversold. The STOCH value of 41.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:DPHA.

Guard Therapeutics International AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:DPHA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:DPHA	47Neutral	SEK 50.56M	-0.36	-151.94%	―	―	70.76%
SE:ACE	44Neutral	SEK 77.45M	-1.20	-62.21%	―	―	58.15%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:MODTX	41Neutral	SEK 31.19M	-1.02	-177.45%	―	―	0.22%
SE:ONCOZ	38Underperform	SEK 85.84M	-1.62	-2775.09%	―	115.26%	-230.43%

* Healthcare Sector Average

Performance Comparison

SE:DPHA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:DPHA	Guard Therapeutics International AB	1.13	-0.24	-17.53%
SE:ONCOZ	OncoZenge AB	3.11	-1.14	-26.75%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:ACE	Ascelia Pharma AB	0.58	-2.63	-81.93%
SE:MODTX	Modus Therapeutics Holding AB	0.18	-0.22	-54.68%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 10, 2026

Guard Therapeutics International AB AI Stock Analysis